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Abstract
Introduction Aggressive treatment with disease-modifying
antirheumatic drugs (DMARDs) plays a major role in improving
early rheumatoid arthritis (RA) patient outcomes. Persistence
and adherence with medication occurs variably (20% to 70%).
The objectives of the study were to determine medication
persistence (MP) in early RA patients over 13 consecutive visits
each 2 months apart, to investigate the relationship between MP
and disease activity, disability and structural damage, and to
identify baseline prognosticators.
Methods Charts from 75 patients of an early RA cohort were
reviewed. At each visit, a rheumatologist interviewed patients
regarding therapy, scored disease activity with the 28-joint
disease activity score (DAS28) and disability with the health
assessment questionnaire (HAQ), and recorded comorbidities
and treatment. A complete medical history was obtained at
baseline. MP was defined as the duration of time from initiation
to discontinuation of at least one DMARD and/or corticosteroids
for at least 1 week and was reported as a dichotomous variable
at consecutive evaluations. Structural damage was defined by
detection of new erosions on radiography. Descriptive statistics,
Student's t test, the chi-squared test, and logistic regression
analyses were used.
Results The proportion of MP patients decreased from 98% at
2 months to 34% at 2 years. MP patients (n = 32) had similar
DAS28 to non-MP patients (n = 53) at initial visits, lower DAS28
and greater DAS28 improvements at follow-ups (P ≤ 0.05 at
visits 4, 6, 7 and 9) and reached sustained remission (≥ 3
consecutive visits with DAS28 < 2.6) more frequently (82.8%
versus 46.5%, P = 0.003) and earlier (7.7 ± 4.6 versus 13.6 ±
5.7 months, P = 0.001) than non-MP patients. MP patients had
similar baseline HAQ scores, but lower HAQ scores at follow-
up (P ≤ 0.05 at visits 3, 5, 6, 7, 9, 10 and 13). More non-MP
patients developed erosive disease than MP patients (26.8%
versus 17.9%, P = 0.56). Older age at baseline was associated
with therapy discontinuation (odds ratio = 1.1, 95% confidence
interval = 1.007 to 1.103, P = 0.02).
Conclusions Discontinuation of DMARDs was frequent and
progressive in an early RA cohort. Patients with persistence on
therapy were younger, had lower disease activity and disability
during follow-up, and reached sustained remission more
frequently and earlier than patients without it. MP should
intentionally be evaluated during follow-up of early RA patients,
as it seems to play a major role in outcome.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that may result in significant disability, morbidity and increased
mortality [1]. In recent years, earlier aggressive treatment with
disease-modifying drugs (DMARDs) has been shown to play a
major role in improving patient outcomes. Those benefits will
be achieved only if patients follow prescribed treatment regi-
mens reasonably closely.
DAS28: 28-joint disease activity score; DMARD: disease modifying anti-rheumatic drug; HAQ: health assessment questionnaire; MP: medication per-
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Both adherence and compliance are words commonly used to
describe how patients take their medication. Traditionally,
adherence to therapy has been defined as 'the number of
patients continuing treatment with a particular drug prescribed
by their health care provider, regardless of the clinical
response' [2,3]. Guidance regarding the meaning of compli-
ance (adherence) and persistence has been proposed
recently [4]. Accordingly, medication compliance (synonym
adherence) is defined as 'the extent to which a patient acts
according to the prescribe interval and dose of a dosing regi-
men' and medication persistence is defined as 'the duration of
time from initiation to discontinuation of therapy' [4].
Compliance to and persistence on medication may be moni-
tored through different methods, direct and indirect, each one
with particular advantages and disadvantages [2,5]. No
method is considered the gold standard. Patient self-reports
are simple, inexpensive and the most useful method in the clin-
ical setting [6,7], although higher rates of adherence/persist-
ence have been reported when patient self-reports are used
for evaluation [5].
Adherence rates are typically higher among patients with
acute conditions as compared with those patients with
chronic conditions. Persistence of adherence among patients
with chronic conditions is disappointedly low and drops dra-
matically after the first 6 months of therapy [8-10]. Efforts had
been made to develop a questionnaire to investigate patient
compliance and persistence with antirheumatic drugs [11-13],
but few studies have examined the topic in chronic inflamma-
tory rheumatic conditions – the majority of these studies
focused on RA treatment. In those studies, different definitions
of adherence and persistence have been used and different
populations and medications evaluated, thus limiting any con-
clusions. The current literature, however, suggests that nonad-
herence to and nonpersistence on DMARD therapy is a
substantial problem, ranging in occurrence from 20% to 70%
[10,14-23].
Many factors have been related to patient's medication behav-
ior in RA patients, including younger age [16,21,23], male sex
[20,21], belonging to an ethnic minority [17], lower education
[17], side effects [17], availability of financial resources and
social support [18,23], medication-taking behavior and beliefs
[19], increased disability [20], better perceived health status
at the beginning [10], poor quality of contact with health pro-
fessionals [20], poor personal knowledge about the disease
and its treatment [20], comorbidity [23] and the class of
DMARDs [10,15,22].
Compliance and persistence with prescribed medication regi-
mens (and placebo regimens) predict better outcomes. Col-
lecting adherence and persistence data from patients is
considered an essential part of clinical trials.
By contrast, poor compliance and nonpersistence with medi-
cation contribute to substantial worsening of disease and
death, and increase healthcare costs [2].
We report our experience with persistence on DMARDs and
corticosteroids evaluated through patient–physician struc-
tured interviews, during 2 years of follow-up of an early RA
cohort of patients. The aims of the study were to determine
persistence on DMARDs and corticosteroids over 13 consec-
utive visits each 2 months apart in a cohort of early RA
patients, to investigate the relationship between persistence
on therapy and disease activity, to investigate the relationship
between persistence on therapy and both disability and struc-
tural damage, and to identify whether any baseline factors are
associated with nonpersistence on medication.
Materials and methods
Setting and study population
The Instituto Nacional de Ciencias Médicas y Nutrición Salva-
dor-Zubirán is a referral centre for Rheumatic Diseases in Méx-
ico City. In February 2004, an early arthritis clinic was
established. Patients with disease duration of less than 1 year
and nonspecific rheumatic diagnosis at initial evaluation but
with RA attended the clinic. As part of the standard care pro-
vided, patients were evaluated at baseline and every 2 months
by the same rheumatologist.
For the present report, we included data for all patients who
attended the clinic for at least 24 months (13 consecutive
evaluations scheduled) up to March 2008: 70 patients com-
pleted 2-year follow-up; additionally, three patients were lost
to follow-up before visit 3, one before visit 8 and another
patient before visit 13. Their data available up to the last obser-
vation were also included in the analysis. As persistence on
therapy was evaluated from the second visit we excluded from
the analysis four additional patients who were lost to follow-up
after baseline evaluation.
Clinical evaluations
Standard baseline and follow-up evaluations included, at
baseline, a complete demographic and medical history
obtained by face-to-face interview, a rheumatic evaluation that
assessed 66 swollen joint counts and 68 tender joint counts,
and a physician global assessment of disease activity on a 100
mm visual analogue scale. Before the medical evaluation, a
Hispanic version of the health assessment questionnaire
(HAQ) [24] and two 100 mm visual analogue scales, one for
pain and one for overall disease activity, were completed by
patients. Laboratory investigations included, at minimum,
determination of rheumatoid factor and C-reactive protein
serum levels (both by nephelometry), a second-generation
ELISA for antibodies to cyclic citrullinated peptides and the
erythrocyte sedimentation rate by the Westergren method.
Disease activity scores were calculated using the 28-joint dis-
ease activity score (DAS28) [25].Available online http://arthritis-research.com/content/11/1/R26
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For the follow-up evaluations, the HAQ, the 100 mm visual
analogue scale for pain, the 100 mm visual analogue scale for
overall disease activity and the physician global assessment of
disease activity on a 100 mm visual analogue scale were com-
pleted by patients and the physician, who additionally per-
formed 66 swollen joint counts and 68 tender joint counts and
scored the DAS28. The erythrocyte sedimentation rate and C-
reactive protein measurements were determined.
Information concerning comorbidities was established by
record review, based on physician diagnosis; in addition, when
a patient was given treatment for a specific diagnosis not
recorded on the charts (for instance, antihypertensive ther-
apy), the corresponding section was updated. Counted
comorbidities were: arterial pulmonary hypertension, arterial
systemic hypertension, asthma, cardiovascular disease, diabe-
tes mellitus, end-stage renal disease, epilepsy, glaucoma,
heart block, hepatic cirrhosis, hepatitis virus B infection, hepa-
titis virus C infection, hydrocephaly, hyperlipidemia, major
depression, obesity, osteoarthritis, osteoporosis, psoriasis,
pulmonary fibrosis, thyroid disorder and vitiligo.
At every visit the same rheumatologist performed a predefined
interview regarding prescriptions. Patients were directed to
refer to the name(s), dose(s) and schedule(s) of the drug(s)
(DMARDs, corticosteroids and other) they had been taking
since the last visit (2 months apart), initially spontaneously and
if necessary directly. Patients were then asked about any miss-
ing/incorrect medication, dose and/or schedule since the pre-
vious visit; emphasis was placed on DMARDs and
corticosteroids. The number of days of missing medication
was also recorded. The rheumatologist compared the last pre-
scription and actual treatment; if inconsistencies were found,
they were solved.
Data were collected in standardized formats.
Radiography
Digitized images of radiographs of the hands and feet (pos-
tero-anterior and oblique views) were scheduled at baseline,
at 1-year and at 2-year follow-up, and were read in chronolog-
ical order by a radiologist and a rheumatologist. RA was clas-
sified as erosive disease (at least one cortical bone defect) or
nonerosive disease, once consensus was reached.
Treatment
Treatment was recorded in standardized formats, including the
use of corticosteroids (yes/no), the use of DMARDs (yes/no),
the number and name(s) of DMARDs/patient and the treat-
ment prescribed for comorbidities. Records included previous
treatment (during the month prior to baseline evaluation) pre-
scribed by physicians who referred patients to the clinic, base-
line treatment prescribed by the rheumatologist in charge of
the clinic at first evaluation, and treatment prescribed at each
follow-up visit.
At baseline and consecutive visits, adverse events were
recorded as part of the standard care provided. Treatment
modifications because of adverse events were not considered
as nonadherence/nonpersistence when indicated by a
physician.
Definitions
Nonpersistence with medication was defined as the duration
of time from initiation to discontinuation of DMARDs and/or
corticosteroids of at least 7 consecutive days. Regarding
methotrexate, at least one weekly missing dose was consid-
ered to meet the nonpersistence definition. Nonpersistence
with therapy was evaluated from the second visit and was
defined by an independent observer according to the informa-
tion recorded on the charts.
Sustained remission was defined at last visit, as three or more
consecutive visits each 2 months apart with a DAS28 below
2.6.
Ethics
Patients agreed to enter the Early Arthritis Clinic and approved
clinical and radiological assessments. Treatment was pre-
scribed by the rheumatologist in charged of the Early Arthritis
Clinic according to patient and disease characteristics. The
study was approved by the Institution Review Board. Written
informed consent was obtained from all participating patients.
Statistics
By definition, persistence is reported as a continuous variable
in terms of the number of days for which therapy was available,
although it may also be reported as a dichotomous variable
measured at the end of a predefined time period [4]. Accord-
ingly, data are presented as the number (%) of patients being
persistent (or nonpersistent) at every consecutive visit.
Descriptive statistics, Student's t test and the chi-squared test
were used as appropriate. Multivariate logistic regression anal-
yses were conducted. To summarize the serial clinical, sero-
logical, treatment and comorbidity measurements, areas under
the curve were calculated by the trapezoid method and are
presented standardized by the length of the study [26]. To
identify baseline predictors of nonpersistence with medica-
tion, different models were constructed. At first, variables that
were significant at P < 0.20 on the univariate analysis were
entered into the multivariate model (age, erythrocyte sedimen-
tation rate and C-reactive protein). We also included in the
final model the baseline variables reported in the literature to
be associated with poor adherence/persistence: male sex,
lower education, socioeconomic status, disability (baseline
HAQ), perceived health status (patient 100 mm visual ana-
logue scale for overall disease activity) and comorbidity
[10,14-20,22,23] – although all of them showed P > 0.20 in
the univariate analysis. At the beginning, saturated models
were tested and the less significant variables were excluded.Arthritis Research & Therapy    Vol 11 No 1    Pascual-Ramos et al.
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Finally, the parsimonious models are reported. Two-tailed P ≤
0.05 was considered significant. Analyses were performed
using the SPSS/PC program (version 12.0; SPSS Inc., Chi-
cago, IL, USA).
Results
Persistence on medication survival function
By March 2008 data from 75 patients had been analyzed and
935 notes reviewed. Of these, 860 notes were evaluated (75
baseline notes excluded) and 71 (8.3%) notes with therapy
discontinuation were identified; most of those notes (80.3%)
recorded that patients were nonpersistent with one DMARD –
29 of them (40.8%) with methotrexate, 23 patients (32.4%)
with chloroquine, 15 patients (21.1%) with sulphasalazine, 11
patients (15.5%) with penicillamine, eight patients (11.3%)
with leflunomide, six patients (8.5%) with minocicline and one
patient (1.4%) with prednisone.
Forty-three patients (57.3%) were nonpersistent on at least
one evaluation and their (mean ± standard deviation (SD))
days of therapy discontinuation were 41.7 ± 25.9. There were
incident nonpersistent patients at each consecutive visit, their
numbers ranging from one patient at visit 7 to seven patients
at visit 4. Among nonpersistent patients, 24 (55.8%) were
nonpersistent at one evaluation and their (mean ± SD) days of
therapy discontinuation were 28.9 ± 16.6; 11 patients
(25.6%) were nonpersistent at two evaluations and accumu-
lated (mean ± SD) 47.6 ± 21.5 days of therapy discontinua-
tion; seven patients (16.3%) were nonpersistent at three
evaluations and had (mean ± SD) 65 ± 22.4 days of therapy
discontinuation; and finally, one patient (2.3%) was nonper-
sistent at four visits and his global period of therapy discontin-
uation was 119 days.
Figure 1 shows the cumulative risk of being persistent on ther-
apy, which decreased from 98% at visit 2 (2.15 ± 0.44 months
of follow-up) to 34% at visit 13 (24.6 ± 6.17 months of follow-
up).
Baseline characteristics of the population studied
As shown in Table 1, baseline demographic and disease char-
acteristics, comorbidities, baseline treatment and previous
treatment (during the month previous to the baseline evalua-
tion at the clinic) were the same in persistent patients and non-
persistent patients but the persistent patients were younger.
Forty-eight percent of the patients from both groups had base-
line positive antinuclear antibodies; fine and gross speckle
were the most frequently reported patterns (68%). The dose
range of current use of corticosteroids at baseline evaluation
was between 5 and 15 mg/day (equivalent to oral prednisone).
Figure 1
Cumulative risk of being persistent on therapy over 2 years of follow-up Cumulative risk of being persistent on therapy over 2 years of follow-up. Persistence decreased from 98% at visit 2 (2.15 ± 0.44 months of follow-
up) to 34% at visit 13 (24.6 ± 6.17 months of follow-up).Available online http://arthritis-research.com/content/11/1/R26
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Relationship between persistence on medication and 
disease activity
Standardized areas under the curve (mean ± SD) for clinical
and serological (erythrocyte sedimentation rate and C-reactive
protein) disease activities were similar between both groups,
as were areas under the curve for the number of comorbidi-
ties/patient and the number of drugs/patient (Table 2).
Persistent patients had similar (mean ± SD) DAS28 at base-
line and at visits 2 and 3 to nonpersistent patients. After 6
months of follow-up, persistent patients had lower (mean ±
SD) consecutive DAS28 than nonpersistent patients and the
differences were statistically significant at visits 4 to 9 and at
visit 13 (P ≤ 0.03), as shown in Figure 2. In addition, persistent
patients had greater improvements in disease activity (meas-
ured by the difference between the DAS28 at the correspond-
ing visit and the baseline DAS28) at every consecutive visit
than nonpersistent patients; differences were statistically sig-
nificant at visit 4 (3.5 ± 1.5 versus 2.6 ± 1.5, P = 0.009), at
visit 6 (4.2 ± 1.5 versus 3.4 ± 1.6, P = 0.04), at visit 7 (4.2 ±
1.5 versus 3.4 ± 1.6, P = 0.04) and at visit 9 (4.3 ± 1.5 versus
3.4 ± 1.5, P = 0.01).
Table 1
Baseline demographic and disease characteristics, treatment and comorbidities between persistent and nonpersistent patients
Variable Persistent-patients (n = 32) Nonpersistent patients (n = 43) P value
Socio-demographic?
Female sex (n (%)) 27 (84.4%) 36 (83.7%) 1
Age at baseline evaluation (years) 36.1 ± 12.6 42.5 ± 13.7 0.04
Years of education 10.2 ± 3.6 10.1 ± 3.8 0.90
Low socioeconomic status (n (%)) 27 (84.4%) 38 (88.8%) 0.87
Single (n (%)) 17 (53%) 18 (42%) 0.36
Disease characteristics
Number of American College of Rheumatology criteria 5.3 ± 0.7 5 ± 1.2 0.23
Time since first symptom (months) 5.5 ± 2.9 5.2 ± 2.7 0.55
Disease activity score (28 joints) 6.3 ± 1.2 6.2 ± 1.3 0.65
Health assessment questionnaire (0 to 3) 1.5 ± 0.8 1.5 ± 0.9 0.91
Physician global assessment of disease activity visual analogue 
scale (0 to 100)
49.1 ± 23 43.8 ± 20.9 0.30
Patient pain visual analogue scale (0 to 100) 60.4 ± 24.8 58.6 ± 26 0.76
Patient overall disease visual analogue scale (0 to 100) 62.1 ± 28 61.1 ± 26.4 0.87
Erythrocyte sedimentation rate (mm/hour) 36.6 ± 26.8 29.8 ± 18.1 0.19
C-reactive protein (mg/dl) 3.4 ± 5.1 2.2 ± 2.9 0.17
Patients with rheumatoid factor (n (%)) 23 (71.9%) 30 (69.8%) 1
Patients with antibodies to cyclic citrullinated peptides (n (%)) 22 (68.8%) 29 (69%)a 1
Patients with comorbidity (n (%)) 12 (38%) 15 (35%) 1
Baseline treatment at the clinic
Corticosteroid use (n (%)) 9 (28.1%) 11 (25.6%) 1
Number of DMARDs/patient 2 ± 0.7 1.8 ± 0.8 0.36
Number of drugs for comorbid conditions/patient 1.75 ± 1.3 1.4 ± 0.8 0.40
Number of total drugs/patient 3.6 ± 1.3 3.4 ± 1.2 0.56
Previous treatment
Corticosteroid use (n (%)) 4 (12.5%) 9 (29.9%) 0.38
DMARD use (n (%)) 11 (34.4%) 12 (27.9%) 0.61
Number of DMARDs/patient (among users) 1.5 ± 0.5 1.4 ± 0.5 0.86
Data presented as the mean ± standard deviation unless otherwise indicated. DMARD, disease-modifying antirheumatic drug. aOne missing data.Arthritis Research & Therapy    Vol 11 No 1    Pascual-Ramos et al.
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Sustained remission definition (at least three consecutive vis-
its with DAS28 < 2.6) required at least 6 months of follow-up.
Seventy-two patients met the follow-up required: 70 patients
completed 13 consecutive visits, one patient underwent seven
consecutive visits and another patient completed 12 consec-
utive visits. More persistent patients had sustained remission
at last follow-up than nonpersistent patients (24 (82.8%) ver-
sus 20 (46.5%) patients, P = 0.003). Among patients who
achieved sustained remission, persistent patients had shorter
follow-up to outcome than nonpersistent patients (7.7 ± 4.5
versus 13.6 ± 5.7 months, P = 0.001).
Relationship between persistence on medication and 
disability
Both groups of patients had similar standardized areas under
the curve for the HAQ (Table 2). Persistent patients had similar
baseline (mean ± SD) HAQ scores to nonpersistent patients.
At each follow-up visit, persistent patients had lower (mean ±
SD) HAQ scores than nonpersistent patients and the differ-
ences were statistically significant at visit 3, at visits 5 to 7, and
at visits 9, 10 and 13, as shown in Figure 3. Finally, persistent
patients had shorter follow-up to the first visit with HAQ score
≤ 0.20 than nonpersistent patients (mean ± SD, 5.2 ± 4 ver-
sus 8.2 ± 5.7 months, P = 0.02).
Relationship between persistence on medication and 
erosive disease
We compared persistence on medication between patients
who did and who did not develop erosive disease according
to radiography. One nonpersistent patient had erosive disease
at baseline and was discarded from the analysis. Five addi-
tional patients did not complete the 2-year follow-up and did
not have corresponding X-ray scans – their data were also
excluded. Finally, 69 patients had X-ray scans performed at 2
years of follow-up: 28 were persistent and 41 were not. More
nonpersistent patients developed erosive disease than
persistent patients but the difference did not reach statistical
significance (5 (17.9%) versus 11 (26.8%), P = 0.56).
Baseline factors associated with nonpersistence on 
medication
In the multivariate model, among the 43 nonpersistent
patients, older age was the only variable to be consistently
associated with nonpersistence on therapy (odds ratio = 1.1,
95% confidence interval = 1.007 to 1.103, P = 0.02) and was
still associated after controlling for early (during the first 12
months of follow-up) nonpersistence versus late (after 12
months of follow-up) nonpersistence. Similar results were
obtained when the model was applied in the 24 patients who
were nonpersistent at only one evaluation during their 2-year
follow-up (older age, odds ratio = 1.04, 95% confidence inter-
val = 1.002 to 1.087, P = 0.04).
Table 2
Standardized AUCs for clinical, serological, comorbidity and treatment serial measurements of persistent and nonpersistent 
patients
AUC for serial assessments Persistent-patients (n = 32) Nonpersistent patients (n = 43) P value
Clinical
Disease activity score (28 joints) 2.83 ± 1.45 3.04 ± 0.89 0.45
66 swollen joint counts 3.65 ± 5.06 3.99 ± 2.86 0.72
68 tender joint counts 4.02 ± 5.16 3.94 ± 2.74 0.94
Physician global assessment of disease activity visual analogue 
scale
11.72 ± 16.46 12.24 ± 7.60 0.87
Patient pain visual analogue scale 11.79 ± 11.42 12.77 ± 7.24 0.65
Patient overall disease visual analogue scale 11.73 ± 12.3 13.19 ± 7.26 0.52
Health assessment questionnaire 0.23 ± 0.36 0.36 ± 0.32 0.23
Serological
Erythrocyte sedimentation rate 16.99 ± 11.97 15.99 ± 9.67 0.69
C-reactive protein 1.18 ± 1.52 0.73 ± 0.69 0.13
Number of comorbidities/patient 1.33 ± 2.4 1.1 ± 1.48 0.62
Treatment
Number of DMARDs/patient 2.31 ± 0.71 2.47 ± 0.71 0.35
Number of drugs for comorbidity/patient 1.81 ± 1.03 1.83 ± 0.88 0.90
Number of total drugs/patient 4.38 ± 1.13 4.61 ± 1.17 0.39
Data presented as the mean ± standard deviation. AUC, area under the curve; DMARD, disease-modifying antirheumatic drug.Available online http://arthritis-research.com/content/11/1/R26
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Discussion
The terminology, definitions and methods to determine adher-
ence and persistence differ greatly in the published literature
[27]. A need for improvement in the quality and consistency of
medication compliance and persistence research is manda-
tory. In 2006 the International Society of Pharmaeconomics
and Outcomes Research published a consensus document
that was intended to improve the consistency and quality of
analysis regarding this topic and to understand the impact of
compliance and adherence on health outcomes [28]. Two
years later, Cramer and colleagues provided specific defini-
tions for compliance and persistence, and encouraged their
adoption by health outcome researchers [4]. In the present
study we have adopted those definitions and analyzed persist-
ence on DMARDs and corticosteroids in early RA patients.
Nonetheless, poor adherence may be related to therapy dis-
continuation (that is, nonpersistence according to the recent
proposal) and most of the published studies do not include
persistence as a separate construct from compliance, which
makes difficult a comprehensive discussion on the topic.
The present study highlights the impact of therapy persistence
on different RA outcomes. After 6 months of follow-up, persist-
ent patients showed lower scores and greater improvements
in disease activity and disability and had more frequent and
earlier sustained remission than nonpersistent patients. It may
be argued that it is not clear whether better outcomes were a
cause of or an effect of persistence on therapy. Nonetheless,
at initial evaluations both groups of patients had similar clinical
status, demography (except age), comorbidities, and disease
characteristics. Treatment at baseline and during follow-up did
not differ between them, suggesting that greater clinical
Figure 2
Comparison of consecutive 28-joint disease activity scores between persistent patients and nonpersistent patients Comparison of consecutive 28-joint disease activity scores between persistent patients and nonpersistent patients. Consecutive 28-joint disease 
activity score (DAS28) for persistent patients (blue bars) and nonpersistent patients (green bars). Thick line in middle of bar, mean DAS28 value; top 
and bottom of bar, upper and lower quartiles, respectively; top and bottom lines, maximum and minimum values, respectively. x axis, consecutive vis-
its (V); y axis, DAS28 values. *Differences with P ≤ 0.05. SD, standard deviation.Arthritis Research & Therapy    Vol 11 No 1    Pascual-Ramos et al.
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improvement in persistent patients was probably related to
persistence on therapy. To the best of our knowledge there is
only one study that has evaluated compliance and RA out-
comes. Viller and colleagues showed more frequent improve-
ment in disability (no relationship with disease activity was
investigated) in consistently compliant European RA patients
over 3 years of follow-up than in those who changed behavior
[21]. They included 556 patients with < 5 years of disease
duration, and compliance with drug dosages and dosing times
was assessed yearly using a questionnaire. We also found that
more nonpersistent patients developed erosive disease than
persistent patients, although the difference was not statisti-
cally significant – we were probably limited by the number of
patients with erosive disease. Interestingly, most nonpersist-
ent patients (56%) omitted treatment once during follow-up;
among them, the number of therapy-discontinuation days was
low (4% of the indicated days of therapy) but impacted nega-
tively on the disease prognosis.
Among potential candidates, older age was the only predictor
to be associated with nonpersistence on DMARD and corti-
costeroid therapy. Kristensen and colleagues identified high
age (in addition to low C-reactive protein serum level, elevated
HAQ score, and higher previous number of DMARDs) as a
predictor of premature treatment termination (which may be
considered a synonym for nonpersistence) with etarnecept
and infliximab in 1,161 patients with active RA [29]. By con-
trast, Viller and colleagues found older age (in addition to
female sex, decreased disability, very satisfactory contacts
with health professionals, and more personal knowledge
about the disease and its treatment) significantly associated
with good compliance in their early RA cohort [20]. Self-
Figure 3
Comparison of consecutive health assessment questionnaire scores between persistent patients and nonpersistent patients Comparison of consecutive health assessment questionnaire scores between persistent patients and nonpersistent patients. Consecutive health 
assessment questionnaire (HAQ) scores for persistent patients (blue bars) and nonpersistent patients (green bars). Thick line in middle of bar, mean 
value; top and bottom of bar, upper and lower quartiles, respectively; top and bottom lines, maximum and minimum values, respectively. x axis, con-
secutive visits (V); y axis, HAQ values. *Differences with P ≤ 0.05. SD, standard deviation.Available online http://arthritis-research.com/content/11/1/R26
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reporting of current medication use with DMARDs (methotrex-
ate, sulphasalazine, and corticosteroids) has been considered
to have good to excellent agreement with information obtained
from the medical charts [30]. In our study, the time between
two visits was 2 months so the treatment recorded could be
considered current treatment; meanwhile, compliance with
drugs was assessed annually in the study of Viller and col-
leagues. Tuncay and colleagues performed three assess-
ments for drug compliance over 1 year of follow-up in 100 RA
patients [16]. Consistently compliant patients were older than
consistently noncompliant patients, although no regression
analysis was performed. In both studies, patients had longer
disease duration than patients from our study and the concept
of medication persistence as a different construct from medi-
cation adherence was not defined. Finally, Curkendall and col-
leagues showed that persistence on (and adherence with)
anti-TNFα was better among older patients, in an inception
cohort of anti-TNFα-naïve-RA patients [23]; worse persist-
ence was also associated with greater out-of-pocket costs,
with higher Charlson's comorbidity score and with previous
prescription for a narcotic analgesic. Adherence and persist-
ence were measured using claims data on a particular RA pop-
ulation of unknown disease duration, which may have
accounted for the different result.
Persistence on therapy decreased in our cohort of early RA
patients up to 34% at 2 years of follow-up. Curkendall and col-
leagues showed that persistence on (and adherence with)
anti-TNFα decreased over 1 year of follow-up in their inception
cohort of RA patients, up to 32% in those patients with out-of-
pockets costs above $50/week [23]. Similar results were
found regarding a decline of compliance by de Klerk and col-
leagues in 127 outpatients, 81 of whom had RA [10]; by Viller
and colleagues, who identified 35.7% of consistently compli-
ant patients after three years of follow-up [20]; and by Tunkay
and colleagues, who found that 30.2% of 100 RA patients
were consistently compliant over 1 year of follow-up [16]. Two
other studies performed in 66 patients and 108 RA patients,
respectively, showed higher rates of compliance and persist-
ence with therapy, ranging from 61% to 73% [15,31]. Numer-
ous randomized clinical trials performed in RA patients had
also assessed drug continuation (persistence) over different
follow-up periods [32-38], although the probability of discon-
tinuation for reasons other than adverse events and lack of effi-
cacy was very low.
The present study has several limitations. We did not use a
well-validated questionnaire scale to assess compliance/per-
sistence [11,13,39]. We assessed persistence through the
simplest and most used way in clinical practice, which is to ask
the patient whether he/she is still taking the medication as pre-
scribed [7,40-43]. We used a partially arbitrary and recently
proposed definition to define nonpersistence. We choose a
lag time of 1 week, as 89% of our patients were taken meth-
otrexate and the drug is indicated weekly. We analyzed neither
the whole spectrum of nonadherence/nonpersistence nor its
repercussion on disease activity and damage – clinical out-
comes of treatment are affected not only by how long patients
take their medication but also by how well; accordingly, adher-
ence should have been defined and measured to characterize
medication-taking behavior comprehensively. In terms of guar-
anteeing a better prognosis, how to define a reasonable
adherence/persistence is still unknown. Finally, the outcome is
not the result of compliance and persistence alone but can be
influenced by many other factors [44]. In that sense, the
present study was carried out in an inception cohort of early
RA patients, with particular sociodemographic characteristics,
ethnicity, treatment and health system, and our results may not
be generalized to RA populations with different characteristics
[45].
In 2006, the American College of Rheumatology endorsed a
starter set of quality indicators for several rheumatic diseases,
among them RA [46,47]. Two measures pertinent to treatment
were included and strategies proposed to be used when there
is increased disease activity or damage progression over a 6-
month period. The recommendations add potential adverse
events, increase costs, and are based on the assumption that
patients are fully (or partially) compliant with therapy and per-
sistent on medication. The present study reinforces the neces-
sity to consistently investigate compliance and persistence
with treatment before regimens are modified. Potential bene-
fits are better prognosis, cost reductions and patient safety.
Conclusion
Nonpersistence on DMARDs was frequent and progressive
over the first 2 years of follow-up in a cohort of early RA
patients, a time frame that has been proposed as crucial for
disease control/remission. Persistent patients were younger at
baseline evaluation and had lower disease activity and disabil-
ity during their follow-up than nonpersistent patients. Persist-
ent patients reached sustained remission more frequently and
earlier than nonpersistent patients. Persistence and adher-
ence with medication should routinely be evaluated during RA
follow-ups, especially at the beginning of the disease when
adequate treatment has a major impact on disease outcomes.
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